With an annual growth twice as fast as that of the total market for medicinal products, biologics represent 35% of pharmaceutical spending in Europe. The use of biosimilars, manufactured using a biotechnological process similar to that of existing biologics and for which the patent is in the public domain, is an important source of savings for health systems, and is growing rapidly. In France, a study conducted by IQVIA showed that biosimilar medicinal products provided a €2.4 billion saving between 2012 and 2022. According to the income and expenses report by French national health insurance, €100 million, including 40 million in 2022 and 2023, could be saved each year if biosimilars could achieve an 80% rate of market penetration. This was the case in the hospital context in 2021, unlike in the outpatient setting, where these medicinal products constitute only 31% of sales volumes for biologics.